Elsevier

The Lancet

Volume 345, Issue 8963, 10 June 1995, Pages 1455-1463
The Lancet

Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial

https://doi.org/10.1016/S0140-6736(95)91034-4Get rights and content

Abstract

Eclampsia, the occurrence of a seizure in association with pre-eclampsia, remains an important cause of maternal mortality. Although it is standard practice to use an anticonvulsant for management of eclampsia, the choice of agent is controversial and there has been little properly controlled evidence to support any of the options. 1687 women with eclampsia were recruited into an international multicentre randomised trial comparing standard anticonvulsant regimens. Primary measures of outcome were recurrence of convulsions and maternal death. Data are available for 1680 (99·6%) women: 453 allocated magnesium sulphate versus 452 allocated diazepam, and 388 allocated magnesium sulphate versus 387 allocated phenytoin. Most women (99%) received the anticonvulsant that they had been allocated. Women allocated magnesium sulphate had a 52% lower risk of recurrent convulsions (95% Cl 64% to 37% reduction) than those allocated diazepam (60 [13·2%] vs 126 [27·9%]; ie, 14·7 [SD 2·6] fewer women with recurrent convulsions per 100 women; 2p<0·00001). Maternal mortality was non-significantly lower among women allocated magnesium sulphate. There were no significant differences in other measures of serious maternal morbidity, or in perinatal morbidity or mortality. Women allocated magnesium sulphate had a 67% lower risk of recurrent convulsions (95% Cl 79% to 47% reduction) than those allocated phenytoin (22 [5·7%] vs 66 [17·1%] ie, 11·4 [SD 2·2] fewer women with recurrent convulsions per 100 women; 2p<0·00001). Maternal mortality was non-significantly lower among women allocated magnesium sulphate. Women allocated magnesium sulphate were also less likely to be ventilated, to develop pneumonia, and to be admitted to intensive care facilities than those allocated phenytoin. The babies of women who had been allocated magnesium sulphate before delivery were significantly less likely to be intubated at the place of delivery, and to be admitted to a special care nursery, than the babies of mothers who had been allocated phenytoin. There is now compelling evidence in favour of magnesium sulphate, rather than diazepam or phenytoin, for the treatment of eclampsia.

References (37)

  • Mp Appleton et al.

    Magnesium sulfate versus phenytoin for seizure prophylaxis in pregnancy-induced hypertension

    Am J Obstet Gynecol

    (1991)
  • G. Ryan et al.

    Clinical experience with phenytoin prophylaxis in severe preeclampsia

    Am J Obstet Gynecol

    (1989)
  • Ka Douglas et al.

    Eclampsia in the United Kingdom

    BMJ

    (1994)
  • CA. Crowther

    Eclampsia at Harare Maternity Hospital. An epidemiological study

    S Afr Med J

    (1985)
  • S. Bergstöm et al.

    Seasonal incidence of eclampsia and its relationship to meteorological data in Mozambique

    J Perinat Med

    (1992)
  • H. Mahler

    The safe motherhood initiative: a call to action

    Lancet

    (1987)
  • L. Duley

    Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean

    Br J Obstet Gynaecol

    (1992)
  • I. Loudon

    Death in childbirth: an international study of maternal care and maternal mortality 1800-1950

    (1992)
  • Cited by (0)

    Correspondence to: Lelia Duley, Perinatal Trials Service, NPEU, Radcliffe Infirmary, Oxford OX2 6HE, UK

    1

    Collaborators and participating centres are listed at the end of the report

    View full text